XML 28 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended
--- | ---
Dec. 28, 2024 | Dec. 30, 2023 | Dec. 31, 2022 | Dec. 25, 2021 | Dec. 26, 2020
Pay vs Performance Disclosure |  |  |  |  |
Pay vs Performance Disclosure, Table | Pay Versus Performance As a result of the rules adopted by the SEC under the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K (“PvP Rules”), we are providing the following information about the relationship between “compensation actually paid” to our CEO (referred to below as our Principal Executive Officer or PEO) and average “compensation actually paid” to our other NEOs and certain metrics of our financial performance for the last three years, in each case, calculated in accordance with the PvP Rules. For purposes of this disclosure, “compensation actually paid” or “CAP” to our PEO and other NEOs represents an amount calculated based on the SEC’s prescribed formula. CAP is not compensation actually earned by or paid to our named executive officers in each respective year. Neither the Compensation Committee nor the executives of our Company directly used the information in this table or the related disclosures when making compensation decisions for 2024. For details about the Company’s pay-for-performance philosophy and how the Compensation Committee makes its decisions about executive pay, see the Compensation Discussion and Analysis beginning on page 34 of this proxy statement. Pay Versus Performance Table
|  |  | Value of initial fixed $100 investment based on |  |  |  |
Year |  |  | Summary Compensation Table Total for PEO |  |  | Compensation Actually Paid to PEO 1 |  |  | Average Summary Compensation Table Total for non-PEO NEOs |  |  | Average Compensation Actually Paid to Non-PEO NEOs 2 |  |  | Total Shareholder Return 3 |  |  | Peer Total Shareholder Return 3 |  |  | Net Income/ (Loss) (in millions) |  |  | Company-Selected Measure: Non-GAAP EPS 4 |
| 2024 |  |  |  | $11,640,272 |  |  |  | $7,852,214 |  |  |  | $3,193,394 |  |  |  | $2,322,504 |  |  |  | $106 |  |  |  | $144 |  |  |  | $398 |  |  |  | $4.74 |
| 2023 |  |  |  | $10,005,729 |  |  |  | $4,941,292 |  |  |  | $2,807,442 |  |  |  | $1,705,337 |  |  |  | $114 |  |  |  | $139 |  |  |  | $436 |  |  |  | $4.50 |
| 2022 |  |  |  | $8,255,135 |  |  |  | $9,962,917 |  |  |  | $2,945,446 |  |  |  | $3,402,202 |  |  |  | $120 |  |  |  | $136 |  |  |  | $566 |  |  |  | $5.38 |
| 2021 |  |  |  | $10,786,180 |  |  |  | $28,293,056 |  |  |  | $3,854,485 |  |  |  | $7,569,084 |  |  |  | $113 |  |  |  | $142 |  |  |  | $660 |  |  |  | $5.05 |
| 2020 |  |  |  | $6,239,637 |  |  |  | ($8,384,241) |  |  |  | $2,649,163 |  |  |  | ($811,730) |  |  |  | $99 |  |  |  | $114 |  |  |  | $419 |  |  |  | $3.53 |
1 The dollar amounts reported in this column represent the CAP to our PEO, Mr. Bergman, as computed in accordance with PvP Rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Bergman during the applicable year. 2 The dollar amounts reported in this column represent the CAP to our Non-PEO NEOs as a group, as computed in accordance with PvP Rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to the Non-PEO NEOs as a group during the applicable year. 3 Cumulative shareholder returns reflect $100 invested as of market close on December 27, 2019, the final trading day of the Company’s fiscal year ended December 28, 2019 (“fiscal 2019”); Peer Total Shareholder Return based on Dow Jones U.S. Health Care Index; see Stock Performance Graph included in Part II, Item 5 of our Annual Report on Form 10-K for the year ended December 28, 2024, as filed with the SEC on February 25, 2025. 4 Reflects the Company’s selected measure of Non-GAAP EPS which is consistently calculated for each year reflected in the table (see chart below). The adjusted EPS used in the incentive plans (HSIP and PSUs) may reflect other adjustments which are generally described in the Compensation Discussion and Analysis.
|  | 2020 |  |  | 2021 |  |  | 2022 |  |  | 2023 |  |  | 2024 |
GAAP diluted EPS from continuing operations attributable to Henry Schein, Inc. |  |  | $2.81 |  |  |  | $4.45 |  |  |  | $3.91 |  |  |  | $3.16 |  |  |  | $3.05 |
Non-GAAP Adjustments, net of tax and attribution to noncontrolling interests: |
Restructuring and integration costs |  |  | $0.17 |  |  |  | $0.03 |  |  |  | $0.74 |  |  |  | $0.40 |  |  |  | $0.62 |
Acquisition intangible amortization |  |  | Excluded |  |  |  | Excluded |  |  |  | Excluded |  |  |  | $0.70 |  |  |  | $0.88 |
Litigation settlements |  |  | - |  |  |  | $0.08 |  |  |  | - |  |  |  | - |  |  |  | $0.03 |
Cybersecurity Incident- insurance proceeds, net of third-party advisory expenses |  |  | - |  |  |  | - |  |  |  | - |  |  |  | $0.06 |  |  |  | $(0.18) |
Impairment of intangible assets |  |  | Excluded |  |  |  | - |  |  |  | $0.16 |  |  |  | $0.04 |  |  |  | - |
Impairment of capitalized assets |  |  | - |  |  |  | - |  |  |  | - |  |  |  | $0.14 |  |  |  | $0.05 |
Change in contingent consideration |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | $0.28 |
Costs associated with shareholder advisory matters |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | $0.01 |
Gain on sale of equity investments |  |  | $(0.01) |  |  |  | $(0.05) |  |  |  | - |  |  |  | - |  |  |  | - |
Non-GAAP diluted EPS attributable to Henry Schein, Inc., as presented |  |  | $2.97 |  |  |  | $4.51 |  |  |  | $4.81 |  |  |  | $4.50 |  |  |  | $4.74 |
Reconciling items to present non-GAAP diluted EPS attributable to Henry Schein, Inc. on a consistent basis: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition intangible amortization |  |  | $0.48 |  |  |  | $0.54 |  |  |  | $0.57 |  |  |  | - |  |  |  | - |
Impairment of intangible assets |  |  | $0.08 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Non-GAAP diluted EPS attributable to Henry Schein, Inc., on a consistent basis 1 |  |  | $3.53 |  |  |  | $5.05 |  |  |  | $5.38 |  |  |  | $4.50 |  |  |  | $4.74 |
1 The Company revised its calculation of non-GAAP diluted EPS in fiscal 2023. As such, the Company adjusted the calculation of non-GAAP diluted EPS for fiscal 2020, fiscal 2021 and fiscal 2022 to be consistent with the calculation of non-GAAP diluted EPS used in fiscal 2023 and fiscal 2024. Reconciliation Tables The following table sets forth a reconciliation from the Summary Compensation Table (“SCT”) to CAP to our PEO. Mr. Bergman served as our only PEO for each year.
Year |  | SCT Total (a) |  | Less Equity Deduction from SCT Total 1 (b) |  | Value of Current Year Equity Awards at Year-end 2 (c) |  | Change in Value of Unvested Prior Year Awards During Year 3 (d) |  | Change in Value of Prior Year Awards That Vested During Year 4 (e) |  | Total Compensation Actually Paid 5 (a + b + c + d + e)
2024 |  | $11,640,272 |  | ($7,764,800) |  | $5,395,792 |  | ($1,428,384) |  | $9,334 |  | $7,852,214
2023 |  | $10,005,729 |  | ($7,395,000) |  | $4,370,663 |  | ($1,726,122) |  | ($313,978) |  | $4,941,292
2022 |  | $8,255,135 |  | ($3,971,000) |  | $2,850,094 |  | $1,434,350 |  | $1,394,338 |  | $9,962,917
2021 |  | $10,786,180 |  | ($5,770,209) |  | $7,378,604 |  | $15,932,034 |  | ($33,552) |  | $28,293,056
2020 |  | $6,239,637 |  | ($3,438,000) |  | $0 |  | ($10,977,620) |  | ($208,258) |  | ($8,384,241)
1 Represents the grant date fair value of equity-based awards made during the fiscal year based on the amounts reported in the “Stock Awards” and “Option Awards” columns in the SCT for the applicable year. 2 Represents the year-end fair value of equity awards that were made during the fiscal year (no grants made during a fiscal year vested during the same fiscal year). 3 Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of year-end. 4 Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that vested during the current fiscal year. 5 SCT total, less SCT equity grant date fair value, plus year-end fair value of equity awards made during the year, plus the change in fair value during the year of equity awards that remained unvested as of year-end, plus the change in fair value of equity awards that vested during the year. The following table sets forth a reconciliation from the SCT to CAP to our average Non-PEO NEO. Our non-PEO NEOs by year are as follows: 2024 and 2023 – Messrs. South, Mlotek, Ettinger and Breslawski; 2022 – Messrs. South, Paladino, Connett, Mlotek and Breslawski; 2021 and 2020 – Messrs. Paladino, Benjamin, Mlotek and Breslawski.
Year |  | SCT Total (a) |  | Less Equity Deduction from SCT Total 1 (b) |  | Value of Current Year Equity Awards at Year-end 2 (c) |  | Change in Value of Unvested Prior Year Awards During Year 3 (d) |  | Change in Value of Prior Year Awards That Vested During Year 4 (e) |  | Total Compensation Actually Paid 5 (a –b + c + d + e)
2024 |  | $3,193,394 |  | ($1,703,125) |  | $1,187,862 |  | ($364,536) |  | $8,909 |  | $2,322,504
2023 |  | $2,807,442 |  | ($1,565,500) |  | $1,063,479 |  | ($555,301) |  | ($44,784) |  | $1,705,337
2022 |  | $2,945,446 |  | ($1,441,433) |  | $1,179,477 |  | $353,110 |  | $365,601 |  | $3,402,202
2021 |  | $3,854,485 |  | ($2,174,430) |  | $2,805,529 |  | $3,118,145 |  | ($34,646) |  | $7,569,084
2020 |  | $2,649,163 |  | ($1,473,250) |  | $560,510 |  | ($2,401,561) |  | ($146,591) |  | ($811,730)
1 Represents the grant date fair value of equity-based awards made during the fiscal year based on the amounts reported in the “Stock Awards” and “Option Awards” columns in the SCT for the applicable year. 2 Represents the year-end fair value of equity awards that were made during the fiscal year (no grants made during a fiscal year vested during the same fiscal year). 3 Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of year-end. 4 Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that vested during the current fiscal year. 5 SCT total, less SCT equity grant date fair value, plus year-end fair value of equity awards made during the year, plus the change in fair value during the year of equity awards that remained unvested as of year-end, plus the change in fair value of equity awards that vested during the year. The Company grants PSUs to executive officers annually, although no such grant was made during 2021. The Company grants RSUs to executive officers annually. Such grants cliff-vest on the fourth anniversary of the grant. During 2021, certain equity awards were granted as RSUs that vested 50% on the first anniversary of the grant in 2022 and 50% on the second anniversary of the grant in 2023. The Company granted stock options to executive officers in 2021 and 2022 as part of the annual equity grant. Grants vest and become exercisable in one-third increments on the first three anniversaries of the grant and expire on the 10 th anniversary of the grant (subject to earlier expiration based on certain employment terminations). Fair values at time of the grant, at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024 were all determined using the Black-Scholes model. The table below summarizes the option fair values and related assumptions used to calculate CAP for fiscal years 2023 and 2024. None of the options granted to NEOs have been exercised as of year-end 2024.
Valuation Purpose for PVP |  | HSIC Stock Price |  | HSIC Option Exercise Price |  | Expected Term (years) |  | Stock Price Volatility |  | Risk-free Interest Rate |  | Dividend Yield |  | Option Fair Value
Year-end 2023 |  | $75.71 |  | $62.71-$86.27 |  | 3.2 – 4.2 |  | 28.5% |  | 3.86% |  | 0% |  | $18.35-$25.58
2024 Vesting |  | $74.58-$76.88 |  | $62.71-$86.27 |  | 3.0 – 4.0 |  | 28.2% |  | 4.17%-4.33% |  | 0% |  | $17.36-$26.22
Year-end 2024 |  | $70.42 |  | $86.27 |  | 3.2 |  | 28.1% |  | 4.50% |  | 0% |  | $12.39
Company Selected Measure Name | Non-GAAP EPS |  |  |  |
Named Executive Officers, Footnote | Our non-PEO NEOs by year are as follows: 2024 and 2023 – Messrs. South, Mlotek, Ettinger and Breslawski; 2022 – Messrs. South, Paladino, Connett, Mlotek and Breslawski; 2021 and 2020 – Messrs. Paladino, Benjamin, Mlotek and Breslawski. |  |  |  |
Peer Group Issuers, Footnote | Cumulative shareholder returns reflect $100 invested as of market close on December 27, 2019, the final trading day of the Company’s fiscal year ended December 28, 2019 (“fiscal 2019”); Peer Total Shareholder Return based on Dow Jones U.S. Health Care Index; see Stock Performance Graph included in Part II, Item 5 of our Annual Report on Form 10-K for the year ended December 28, 2024, as filed with the SEC on February 25, 2025. |  |  |  |
PEO Total Compensation Amount | $ 11,640,272 | $ 10,005,729 | $ 8,255,135 | $ 10,786,180 | $ 6,239,637
PEO Actually Paid Compensation Amount | $ 7,852,214 | 4,941,292 | 9,962,917 | 28,293,056 | (8,384,241)
Adjustment To PEO Compensation, Footnote | Reconciliation Tables The following table sets forth a reconciliation from the Summary Compensation Table (“SCT”) to CAP to our PEO. Mr. Bergman served as our only PEO for each year.
Year |  | SCT Total (a) |  | Less Equity Deduction from SCT Total 1 (b) |  | Value of Current Year Equity Awards at Year-end 2 (c) |  | Change in Value of Unvested Prior Year Awards During Year 3 (d) |  | Change in Value of Prior Year Awards That Vested During Year 4 (e) |  | Total Compensation Actually Paid 5 (a + b + c + d + e)
2024 |  | $11,640,272 |  | ($7,764,800) |  | $5,395,792 |  | ($1,428,384) |  | $9,334 |  | $7,852,214
2023 |  | $10,005,729 |  | ($7,395,000) |  | $4,370,663 |  | ($1,726,122) |  | ($313,978) |  | $4,941,292
2022 |  | $8,255,135 |  | ($3,971,000) |  | $2,850,094 |  | $1,434,350 |  | $1,394,338 |  | $9,962,917
2021 |  | $10,786,180 |  | ($5,770,209) |  | $7,378,604 |  | $15,932,034 |  | ($33,552) |  | $28,293,056
2020 |  | $6,239,637 |  | ($3,438,000) |  | $0 |  | ($10,977,620) |  | ($208,258) |  | ($8,384,241)
1 Represents the grant date fair value of equity-based awards made during the fiscal year based on the amounts reported in the “Stock Awards” and “Option Awards” columns in the SCT for the applicable year. 2 Represents the year-end fair value of equity awards that were made during the fiscal year (no grants made during a fiscal year vested during the same fiscal year). 3 Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of year-end. 4 Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that vested during the current fiscal year. 5 SCT total, less SCT equity grant date fair value, plus year-end fair value of equity awards made during the year, plus the change in fair value during the year of equity awards that remained unvested as of year-end, plus the change in fair value of equity awards that vested during the year. The Company granted stock options to executive officers in 2021 and 2022 as part of the annual equity grant. Grants vest and become exercisable in one-third increments on the first three anniversaries of the grant and expire on the 10 th anniversary of the grant (subject to earlier expiration based on certain employment terminations). Fair values at time of the grant, at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024 were all determined using the Black-Scholes model. The table below summarizes the option fair values and related assumptions used to calculate CAP for fiscal years 2023 and 2024. None of the options granted to NEOs have been exercised as of year-end 2024.
Valuation Purpose for PVP |  | HSIC Stock Price |  | HSIC Option Exercise Price |  | Expected Term (years) |  | Stock Price Volatility |  | Risk-free Interest Rate |  | Dividend Yield |  | Option Fair Value
Year-end 2023 |  | $75.71 |  | $62.71-$86.27 |  | 3.2 – 4.2 |  | 28.5% |  | 3.86% |  | 0% |  | $18.35-$25.58
2024 Vesting |  | $74.58-$76.88 |  | $62.71-$86.27 |  | 3.0 – 4.0 |  | 28.2% |  | 4.17%-4.33% |  | 0% |  | $17.36-$26.22
Year-end 2024 |  | $70.42 |  | $86.27 |  | 3.2 |  | 28.1% |  | 4.50% |  | 0% |  | $12.39
Non-PEO NEO Average Total Compensation Amount | $ 3,193,394 | 2,807,442 | 2,945,446 | 3,854,485 | 2,649,163
Non-PEO NEO Average Compensation Actually Paid Amount | $ 2,322,504 | 1,705,337 | 3,402,202 | 7,569,084 | (811,730)
Adjustment to Non-PEO NEO Compensation Footnote | The following table sets forth a reconciliation from the SCT to CAP to our average Non-PEO NEO. Our non-PEO NEOs by year are as follows: 2024 and 2023 – Messrs. South, Mlotek, Ettinger and Breslawski; 2022 – Messrs. South, Paladino, Connett, Mlotek and Breslawski; 2021 and 2020 – Messrs. Paladino, Benjamin, Mlotek and Breslawski.
Year |  | SCT Total (a) |  | Less Equity Deduction from SCT Total 1 (b) |  | Value of Current Year Equity Awards at Year-end 2 (c) |  | Change in Value of Unvested Prior Year Awards During Year 3 (d) |  | Change in Value of Prior Year Awards That Vested During Year 4 (e) |  | Total Compensation Actually Paid 5 (a –b + c + d + e)
2024 |  | $3,193,394 |  | ($1,703,125) |  | $1,187,862 |  | ($364,536) |  | $8,909 |  | $2,322,504
2023 |  | $2,807,442 |  | ($1,565,500) |  | $1,063,479 |  | ($555,301) |  | ($44,784) |  | $1,705,337
2022 |  | $2,945,446 |  | ($1,441,433) |  | $1,179,477 |  | $353,110 |  | $365,601 |  | $3,402,202
2021 |  | $3,854,485 |  | ($2,174,430) |  | $2,805,529 |  | $3,118,145 |  | ($34,646) |  | $7,569,084
2020 |  | $2,649,163 |  | ($1,473,250) |  | $560,510 |  | ($2,401,561) |  | ($146,591) |  | ($811,730)
1 Represents the grant date fair value of equity-based awards made during the fiscal year based on the amounts reported in the “Stock Awards” and “Option Awards” columns in the SCT for the applicable year. 2 Represents the year-end fair value of equity awards that were made during the fiscal year (no grants made during a fiscal year vested during the same fiscal year). 3 Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of year-end. 4 Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that vested during the current fiscal year. 5 SCT total, less SCT equity grant date fair value, plus year-end fair value of equity awards made during the year, plus the change in fair value during the year of equity awards that remained unvested as of year-end, plus the change in fair value of equity awards that vested during the year. The Company grants PSUs to executive officers annually, although no such grant was made during 2021. The Company grants RSUs to executive officers annually. Such grants cliff-vest on the fourth anniversary of the grant. During 2021, certain equity awards were granted as RSUs that vested 50% on the first anniversary of the grant in 2022 and 50% on the second anniversary of the grant in 2023. The Company granted stock options to executive officers in 2021 and 2022 as part of the annual equity grant. Grants vest and become exercisable in one-third increments on the first three anniversaries of the grant and expire on the 10 th anniversary of the grant (subject to earlier expiration based on certain employment terminations). Fair values at time of the grant, at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024 were all determined using the Black-Scholes model. The table below summarizes the option fair values and related assumptions used to calculate CAP for fiscal years 2023 and 2024. None of the options granted to NEOs have been exercised as of year-end 2024.
Valuation Purpose for PVP |  | HSIC Stock Price |  | HSIC Option Exercise Price |  | Expected Term (years) |  | Stock Price Volatility |  | Risk-free Interest Rate |  | Dividend Yield |  | Option Fair Value
Year-end 2023 |  | $75.71 |  | $62.71-$86.27 |  | 3.2 – 4.2 |  | 28.5% |  | 3.86% |  | 0% |  | $18.35-$25.58
2024 Vesting |  | $74.58-$76.88 |  | $62.71-$86.27 |  | 3.0 – 4.0 |  | 28.2% |  | 4.17%-4.33% |  | 0% |  | $17.36-$26.22
Year-end 2024 |  | $70.42 |  | $86.27 |  | 3.2 |  | 28.1% |  | 4.50% |  | 0% |  | $12.39
Compensation Actually Paid vs. Total Shareholder Return | The following chart sets forth the relationship between PEO CAP, the average of other NEOs CAP and our TSR during fiscal years 2020 through 2024 versus the Dow Jones U.S. Health Care Index. |  |  |  |
Compensation Actually Paid vs. Net Income | The following chart sets forth the relationship between PEO CAP, the average of other NEOs CAP and our net income during fiscal years 2020 through 2024. |  |  |  |
Compensation Actually Paid vs. Company Selected Measure | The following chart sets forth the relationship between PEO CAP, the average of other NEOs CAP and our non-GAAP EPS during fiscal years 2020 through 2024. |  |  |  |
Total Shareholder Return Vs Peer Group | The following chart sets forth the relationship between PEO CAP, the average of other NEOs CAP and our TSR during fiscal years 2020 through 2024 versus the Dow Jones U.S. Health Care Index. |  |  |  |
Tabular List, Table | Most Important Financial Measures The following table sets forth financial performance measures that we considered to be the most important in how CAP was linked to Company performance during 2024. As discussed in the Compensation Discussion and Analysis beginning on page 34 of this proxy statement, the annual HSIP uses adjusted EPS as a financial metric for all NEOs and cumulative EPS is a financial metric used for PSU grants for the 2020-2022, 2022-2024, 2023-2025 and 2024-2026 cycles (no PSU grants were made for 2021-2023). The annual HSIP also uses revenue and operating income as a financial metric for our NEOs. The PSU grants for the 2023-2025 and 2024-2026 cycle also include Return on Invested Capital as a financial metric.
Key Financial Measures |  |  |  |  |  |
Adjusted EPS 1 |  |  |  |  |  |
Revenues 2 |  |  |  |  |  |
Operating Income 3 |  |  |  |  |  |
Return on Invested Capital 4 |  |  |  |  |  |
Total Shareholder Return Amount | $ 106 | 114 | 120 | 113 | 99
Peer Group Total Shareholder Return Amount | 144 | 139 | 136 | 142 | 114
Net Income (Loss) | $ 398,000,000 | $ 436,000,000 | $ 566,000,000 | $ 660,000,000 | $ 419,000,000
Company Selected Measure Amount | 4.74 | 4.5 | 5.38 | 5.05 | 3.53
PEO Name | Mr. Bergman |  |  |  |
Percentage of Award Vesting |  | 50.00% | 50.00% |  |
Stock Price Maximum | $ 70.42 | $ 75.71 |  |  |
Option Exercise Price Minimum |  | 62.71 |  |  |
Option Exercise Price Maximum | $ 86.27 | $ 86.27 |  |  |
Expected Term Minimum |  | 3 years 2 months 12 days |  |  |
Expected Term Maximum | 3 years 2 months 12 days | 4 years 2 months 12 days |  |  |
Stock Price Volatility Maximum | 28.10% | 28.50% |  |  |
Riskfree Interest Rate Maximum | 4.50% | 3.86% |  |  |
Dividend Yield | 0.00% | 0.00% |  |  |
Option Fair Value Minimum |  | $ 18.35 |  |  |
Option Fair Value Maximum | $ 12.39 | $ 25.58 |  |  |
Measure:: 1 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Adjusted EPS |  |  |  |
Non-GAAP Measure Description | Reflects the Company’s selected measure of Non-GAAP EPS which is consistently calculated for each year reflected in the table (see chart below). The adjusted EPS used in the incentive plans (HSIP and PSUs) may reflect other adjustments which are generally described in the Compensation Discussion and Analysis. |  |  |  |
Measure:: 2 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Revenues |  |  |  |
Measure:: 3 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Operating Income |  |  |  |
Measure:: 4 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Return on Invested Capital |  |  |  |
Vesting Awards [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Stock Price Minimum | $ 74.58 |  |  |  |
Stock Price Maximum | 76.88 |  |  |  |
Option Exercise Price Minimum | 62.71 |  |  |  |
Option Exercise Price Maximum | $ 86.27 |  |  |  |
Expected Term Minimum | 3 years |  |  |  |
Expected Term Maximum | 4 years |  |  |  |
Stock Price Volatility Maximum | 28.20% |  |  |  |
Riskfree Interest Rate Minimum | 4.17% |  |  |  |
Riskfree Interest Rate Maximum | 4.33% |  |  |  |
Dividend Yield | 0.00% |  |  |  |
Option Fair Value Minimum | $ 17.36 |  |  |  |
Option Fair Value Maximum | $ 26.22 |  |  |  |
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ (7,764,800) | $ (7,395,000) | $ (3,971,000) | $ (5,770,209) | $ (3,438,000)
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 5,395,792 | 4,370,663 | 2,850,094 | 7,378,604 | 0
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (1,428,384) | (1,726,122) | 1,434,350 | 15,932,034 | (10,977,620)
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 9,334 | (313,978) | 1,394,338 | (33,552) | (208,258)
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (1,703,125) | (1,565,500) | (1,441,433) | (2,174,430) | (1,473,250)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 1,187,862 | 1,063,479 | 1,179,477 | 2,805,529 | 560,510
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (364,536) | (555,301) | 353,110 | 3,118,145 | (2,401,561)
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ 8,909 | $ (44,784) | $ 365,601 | $ (34,646) | $ (146,591)

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_NonGaapMeasureDescriptionTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share based payment award, fair value assumptions, expected dividend rate + References No definition available. + Details
Name: | hsic_DividendYield
Namespace Prefix: | hsic_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share Based payment award fair value assumptions expected term maximum. + References No definition available. + Details
Name: | hsic_ExpectedTermMaximum
Namespace Prefix: | hsic_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share Based payment award fair value assumptions expected term minimum. + References No definition available. + Details
Name: | hsic_ExpectedTermMinimum
Namespace Prefix: | hsic_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share based payment award fair value assumptions option exercise price maximum. + References No definition available. + Details
Name: | hsic_OptionExercisePriceMaximum
Namespace Prefix: | hsic_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share based payment award fair value assumptions option exercise price minimum. + References No definition available. + Details
Name: | hsic_OptionExercisePriceMinimum
Namespace Prefix: | hsic_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share based payment award, fair value assumptions, option maximum. + References No definition available. + Details
Name: | hsic_OptionFairValueMaximum
Namespace Prefix: | hsic_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share based payment award, fair value assumptions, option minimum. + References No definition available. + Details
Name: | hsic_OptionFairValueMinimum
Namespace Prefix: | hsic_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Vesting Of Restricted Stock Unit Award Under Share based Payment Arrangement. + References No definition available. + Details
Name: | hsic_PercentageofAwardVesting
Namespace Prefix: | hsic_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share-based payment award, fair value assumptions, risk free interest rate maximum. + References No definition available. + Details
Name: | hsic_RiskfreeInterestRateMaximum
Namespace Prefix: | hsic_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share based payment award, fair value assumptions, risk free interest rate minimum. + References No definition available. + Details
Name: | hsic_RiskfreeInterestRateMinimum
Namespace Prefix: | hsic_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share based payment award fair value assumptions stock price maximum. + References No definition available. + Details
Name: | hsic_StockPriceMaximum
Namespace Prefix: | hsic_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share based payment award fair value assumptions stock price minimum. + References No definition available. + Details
Name: | hsic_StockPriceMinimum
Namespace Prefix: | hsic_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share Based payment award, fair value assumptions, expected volatility rate maximum. + References No definition available. + Details
Name: | hsic_StockPriceVolatilityMaximum
Namespace Prefix: | hsic_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=4
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=hsic_VestingAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |